IL159898A0 - Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide - Google Patents

Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide

Info

Publication number
IL159898A0
IL159898A0 IL15989802A IL15989802A IL159898A0 IL 159898 A0 IL159898 A0 IL 159898A0 IL 15989802 A IL15989802 A IL 15989802A IL 15989802 A IL15989802 A IL 15989802A IL 159898 A0 IL159898 A0 IL 159898A0
Authority
IL
Israel
Prior art keywords
mammals
nitric oxide
pulmonary disease
disease states
treating pulmonary
Prior art date
Application number
IL15989802A
Other languages
English (en)
Original Assignee
Cellular Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Sciences Inc filed Critical Cellular Sciences Inc
Publication of IL159898A0 publication Critical patent/IL159898A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15989802A 2001-08-21 2002-08-15 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide IL159898A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31387201P 2001-08-21 2001-08-21
PCT/US2002/026060 WO2003017996A1 (en) 2001-08-21 2002-08-15 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide

Publications (1)

Publication Number Publication Date
IL159898A0 true IL159898A0 (en) 2004-06-20

Family

ID=23217517

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15989802A IL159898A0 (en) 2001-08-21 2002-08-15 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide

Country Status (8)

Country Link
US (1) US6689810B2 (xx)
EP (1) EP1427402A4 (xx)
JP (1) JP2005501106A (xx)
AU (1) AU2002329762B2 (xx)
CA (1) CA2457983C (xx)
IL (1) IL159898A0 (xx)
MX (1) MXPA04000993A (xx)
WO (1) WO2003017996A1 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20030105162A1 (en) * 2001-08-21 2003-06-05 Celluar Sciences, Inc. Method for treating bronchial constriction and bronchospasm
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
US20040220265A1 (en) * 2002-07-25 2004-11-04 Celluar Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US20080213403A1 (en) * 2002-07-25 2008-09-04 Alain Martin Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
PT1542670E (pt) * 2002-09-24 2013-07-11 Suntory Holdings Ltd Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
CA2413834A1 (en) * 2002-12-10 2004-06-10 1017975 Alberta Limited Nitric oxide gas generator
US9138707B2 (en) 2002-12-10 2015-09-22 Sy Kimball Portable, nitric oxide generator
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US8017074B2 (en) 2004-01-07 2011-09-13 Noxilizer, Inc. Sterilization system and device
CA2552735C (en) 2004-01-07 2012-09-11 Noxilizer, Inc. Sterilization system and device
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US20080008771A1 (en) * 2004-05-27 2008-01-10 Children's Hospital Medical Center Nitric Oxide Dioxygenase Inhibitors
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
AU2005316295B2 (en) * 2004-12-17 2012-03-22 Alan B. Cash Method for extending lifespan and delaying the onset of age-related disease
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
WO2007101068A2 (en) * 2006-02-22 2007-09-07 Puricore, Inc. Methods of treating cystic fibrosis
CA2647859C (en) 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8211943B2 (en) * 2007-08-08 2012-07-03 Alain Martin Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US8114907B2 (en) * 2007-08-08 2012-02-14 Cellular Sciences Inc Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US9675569B2 (en) * 2007-08-08 2017-06-13 Alain Martin Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
HUE043235T2 (hu) * 2008-01-31 2019-08-28 Univ Vanderbilt Terápiás kezelések tüdõbetegségekhez
KR101932831B1 (ko) 2008-01-31 2018-12-27 반더빌트유니버시티 관상과 동맥의 동맥류성 지주막하출혈의 치료를 위한 조성물 및 방법
US20100040703A1 (en) * 2008-08-13 2010-02-18 Chris Miller Use of nitric oxide
JP5611955B2 (ja) 2008-09-22 2014-10-22 ゲノ エルエルシー 二酸化窒素（ｎｏ２）の一酸化窒素（ｎｏ）への変換
WO2010096766A1 (en) 2009-02-23 2010-08-26 Noxilizer, Inc. Device and method for gas sterilization
WO2014046603A1 (en) 2012-09-19 2014-03-27 Grespo Ab Compositions for improvement of brain function
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
US20160124002A1 (en) * 2013-06-14 2016-05-05 Seoul National University R&Db Foundation Method for detecting hypoxia or diagnosing hypoxia-related diseases
EP3195168B1 (en) * 2014-07-31 2022-09-07 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
US20200237815A1 (en) * 2017-02-24 2020-07-30 Alain Martin Methods for treatment of lung damage and for inhibition of lung fibrosis
US11311505B2 (en) * 2017-02-24 2022-04-26 Cellular Sciences, Inc. Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
CN114340609A (zh) * 2019-08-06 2022-04-12 连云港金康和信药业有限公司 产生安全量的一氧化氮的药物组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158883A (en) * 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
US5296370A (en) * 1990-10-04 1994-03-22 Rutgers, The State University Repair medium for the resuscitation of injured cells
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
CA2205112C (en) * 1995-09-19 2008-11-18 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response

Also Published As

Publication number Publication date
US20030040542A1 (en) 2003-02-27
EP1427402A4 (en) 2007-12-05
JP2005501106A (ja) 2005-01-13
CA2457983A1 (en) 2003-03-06
MXPA04000993A (es) 2004-04-20
AU2002329762B2 (en) 2007-03-01
CA2457983C (en) 2011-09-06
EP1427402A1 (en) 2004-06-16
WO2003017996A1 (en) 2003-03-06
US6689810B2 (en) 2004-02-10

Similar Documents

Publication Publication Date Title
IL159898A0 (en) Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
ZA200700904B (en) Method of treating sjögren's syndrome
IL157161A (en) Methods for treating disease states comprising administration of low levels of antibodies
HK1158493A1 (en) Hair treatment agent composition and method for production thereof
GB2393202B (en) Methods of well treatment
EP1450816A4 (en) METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION
AU5939901A (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1667730A4 (en) COMPOSITIONS AND METHOD FOR TREATING INFLAMMATORY LUNG DISEASE
EP1642592A4 (en) MEANS FOR THE TREATMENT OF SARCOIDOSIS AND TREATMENT METHOD THEREFOR
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
EP1347051A4 (en) METHOD FOR EXAMINING AN ALLERGIC DISEASE
PL368935A1 (en) Methods of treating pulmonary disease
EP1425021A4 (en) PHYSIOLOGICAL PROCESS FOR IMPROVING TONGUE
EP1660116A4 (en) METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
IL150963A0 (en) Method and compositions for treating an inflammatory disease
EP1389105A4 (en) METHOD OF TREATMENT
GB0120147D0 (en) Treatment method
GB0112216D0 (en) Method of treatment
EP1284289A4 (en) METHOD OF STUDYING ALLERGIC DISEASES
EP1427429A4 (en) COMPOSITIONS AND METHODS FOR TREATING HYPERGLYCEMIA SUBJECTS
EP1681988A4 (en) METHOD FOR DIAGNOSING AND TREATING PULMONARY DISORDERS
EP1637162A4 (en) MEDICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF IMMUNOLOGICAL ILLNESSES TH1 TYPE
GB0118892D0 (en) Method of treatment
AU2002338894A1 (en) Methods and compositions for treating respiratory mucin production associated disease conditions